Also known as: Abrysvo
A French cohort study found nirsevimab at birth reduces RSV-related hospitalizations in infants by 22% compared to maternal vaccination. UK data shows the maternal RSV vaccine provides over 80% protection when given at least four weeks before birth. Both strategies aim to protect vulnerable infants during their first months of life.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
GSK's RSV vaccine Arexvy received expanded FDA approval to cover all high-risk adults, adding approximately 21 million Americans under 50 to the eligible population and matching competitor approvals from Pfizer and Moderna.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07249320 |
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants |
ACTIVE_NOT_RECRUITING | |
| NCT07235397 |
Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset |
NOT_YET_RECRUITING |
